U.S. GLP-1 Labels Still Lack a NAION Warning as FDA Review Drags On

What Happened

The U.S. prescribing information for Ozempic, Wegovy, Rybelsus, and Mounjaro still carries no warning for NAION — non-arteritic anterior ischemic optic neuropathy, a sudden loss of blood flow to the optic nerve that can permanently damage sight — even though the FDA has been publicly tracking the signal for well over a year.

The FDA's quarterly list of potential safety signals, covering October through December 2024, named GLP-1 receptor agonists — including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound — alongside NAION, with the agency stating it was "evaluating the need for regulatory action." A year and a half later, that evaluation has not produced a U.S. label change.

Regulators elsewhere have not waited:

• The European Medicines Agency concluded in June 2025 that NAION is a very rare side effect of semaglutide — on the order of up to 1 in 10,000 people — citing studies suggesting roughly doubled NAION risk in adults with type 2 diabetes. It advised patients with sudden vision loss to seek care without delay and to stop semaglutide if NAION is confirmed.
• The World Health Organization issued a safety alert echoing that finding the same month.
• Australia's Therapeutic Goods Administration went further in July 2026, adding class-wide NAION warnings that also cover Mounjaro, Trulicity, and Saxenda.

Who Is Affected

• U.S. prescribers, whose risk discussions with patients are shaped by label language
• Patients, who may first learn of the risk from litigation coverage rather than a medication guide
• The manufacturers, facing consolidated vision-loss litigation in which plaintiffs' lead counsel argues the absence of a U.S. warning disadvantages clinicians and patients
• Research-chemical buyers, who receive no labeling protections of any kind

Timeline

• March 2025 — The FDA's quarterly signal list publicly links GLP-1 receptor agonists to NAION; the agency says it is "evaluating the need for regulatory action"
• June 2025 — The EMA concludes NAION is a very rare semaglutide side effect; the FDA's Sentinel analysis of the risk begins and remains listed as in progress
• June 2025 — A WHO alert echoes the European finding
• July 2026 — Australia's TGA adds class-wide NAION warnings for GLP-1 medicines
• August 2026 — U.S. tirzepatide labels are revised — but only for diabetic retinopathy complications, a separate eye risk. No NAION language appears
• October 2026 — U.S. labels still lack any NAION warning as litigation continues to grow

What This Means for Researchers

The transatlantic divergence is a case study in regulatory lag: a signal can be publicly acknowledged by a regulator and still take years to reach prescribing information. The FDA's Sentinel analysis of NAION risk, posted in mid-2025 using insurance-claims data, remains unfinished — leaving U.S. labels unchanged while European and Australian patients receive updated warnings.

For the research market the lesson is starker. Unlicensed compounds never carry a label at all. Anyone sourcing GLP-1 analogs outside the regulated supply chain assumes the entire label-free risk: no contraindication screening, no adverse-event surveillance, no potency guarantee — and no warning if a rare serious adverse event is ever identified.

How to Verify Your Peptides

Whether a vial contains what its label claims is independently checkable:

• Learn how independent testing works
• Compare HPLC and LC-MS testing methods
• Understand identity, purity, and fill-weight checks

Safe Alternatives

• Review our peptide research pages for evidence-based compound profiles
• Consult the vendor transparency listings before any purchase
• Read our semaglutide overview

Sources

Regulatory announcements from the FDA, the European Medicines Agency, the World Health Organization, and Australia's Therapeutic Goods Administration; industry reports on GLP-1 safety labeling.